Early tissue responses to etanercept in psoriasis lesions

GSE47751

Homo sapiens

34 Downloadable Samples

Affymetrix Human Genome U133 Plus 2.0 Array (hgu133plus2)

Submitter Supplied Information

Description

Anti-TNF-alpha therapy has made a significant impact on the treatment of psoriasis. Despite being designed to neutralize TNF-alpha activity, the mechanism of action of these agents in the resolution of psoriasis remains unclear. The aim of this study was to better understand the mechanism of action of etanercept by examining very early changes in the lesional skin of psoriasis patients. 20 chronic plaque psoriasis patients were enrolled and received 50mg etanercept twice weekly. Skin biopsies were obtained before treatment and on days 1, 3, 7 and 14 post-treatment. Skin mRNA expression was analysed by microarray.

PubMed ID

24601997

Publication Title

Early tissue responses in psoriasis to the antitumour necrosis factor-α biologic etanercept suggest reduced interleukin-17 receptor expression and signalling.

Total Samples

Submitter’s Institution

Harvard University

Authors

Johnston A, Guzman AM, Swindell WR, Wang F, Kang S, Gudjonsson JE

Source Repository

Gene Expression Omnibus (GEO)

Alternate Accession IDs

E-GEOD-47751

No rows found